Literature DB >> 311233

Positive antinuclear factor tests with prazosin.

A J Marshall, M E McGraw, D W Barritt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 311233      PMCID: PMC1597589          DOI: 10.1136/bmj.1.6157.165

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  3 in total

1.  Prazosin treatment complicated by acute febrile polyarthritis.

Authors:  S A Cairns; S C Jordan
Journal:  Br Med J       Date:  1976-12-11

2.  Cardiogenic Dementia.

Authors: 
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

3.  Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; K G Wakim; J W Worthington; L E Ward
Journal:  Medicine (Baltimore)       Date:  1967-01       Impact factor: 1.889

  3 in total
  6 in total

1.  Hydrallazine-induced SLE-like syndrome presenting as a leg ulcer.

Authors:  M W Kissin; R C Williamson
Journal:  Br Med J       Date:  1979-11-24

2.  Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.

Authors:  S Caponnetto; E Valvo; P Mocarelli; D Alberti; S Savonitto
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Adverse effects of antihypertensive drugs.

Authors:  F E Husserl; F H Messerli
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

Review 4.  Adverse effects of alpha 1-adrenergic blocking drugs.

Authors:  S G Carruthers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 5.  Acetylator phenotype and lupus erythematosus.

Authors:  J P Uetrecht; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 6.  Antinuclear antibodies and cardiovascular drugs.

Authors:  J D Wilson
Journal:  Drugs       Date:  1980-04       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.